Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3179703 | 1.00 | NR1H2 (0.41) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL13812253 | 0.87 | SLC6A9 (0.44) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL23235715 | 0.87 | SLC6A9 (0.44) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1673065 | 0.86 | SLC6A9 (0.43) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL15347416 | 0.86 | SLC6A9 (0.43) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL3315088 | 0.84 | NR1H2 (0.40) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL3319602 | 0.84 | NR1H2 (0.40) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL17477192 | 0.84 | NR1H2 (0.44) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL13442980 | 0.84 | NR1H2 (0.44) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL17477191 | 0.84 | NR1H2 (0.44) | NR1H2MEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125795-B1 | INDOLE DERIVATIVES | MSD OSS BV (NL) | 2013-03-20 | — | — | EP | disclosed |
| US-7655645-B2 | Analgesics; neuropathic pain, cancer pain, multiple sclerosis | N.V. ORGANON (NL) | 2010-02-02 | — | — | US | disclosed |
| CN-101616914-A | Indole derivatives | ORGANON NV | 2009-12-30 | — | — | CN | disclosed |
| US-20080207598-A1 | INDOLE DERIVATIVES | N.V. ORGANON (NL) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207598-A1 | INDOLE DERIVATIVES | CNR1, CNR2, OPRD1 | NR1H2 63/4885MEN1 2578/4885ALDH1A1 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.